Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C R Franks

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
European Cytokine Network|August 1, 1990
Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapyM Favrot, R Capdeville, V Combaret, et al.
Journal of Biological Response Modifiers|April 1, 1990
Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinomaM C Favrot, V Combaret, S Negrier, et al.
Pediatric Hematology and Oncology|January 1, 1990
Interleukin 2 immunotherapy in children with neuroblastoma after high-dose chemotherapy and autologous bone marrow transplantationM C Favrot, J Michon, D Floret, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
A phase III study of recombinant interleukin-2, 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal carcinomaS D Heys, O Eremin, E M Ruggeri, et al.
British Journal of Haematology|October 1, 1990
Increased numbers of circulating haematopoietic progenitor cells after treatment with high-dose interleukin-2 in cancer patientsM R Schaafsma, W E Fibbe, D van der Harst, et al.
Molecular Biotherapy|September 1, 1990
Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experienceH Kirchner, A Körfer, P A Palmer, et al.
Bone Marrow Transplantation|September 1, 1989
Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantationM C Favrot, D Floret, S Negrier, et al.
Cancer Immunology, Immunotherapy : CII|July 1, 1994
Persistent augmentation of natural-killer- and T-cell-mediated cytotoxicity in peripheral blood mononuclear cells pulsed in vitro with high-dose recombinant interleukin-2 prior to culturing with a low maintenance doseP A Palmer, J G Scharenberg, B M von Blomberg, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Combination IL-2 and cisplatinum: a promising treatment for bronchioloalveolar carcinoma?V Trillet-Lenoir, D Arpin, A Mercatello, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
The development of anti-interleukin-2 (IL-2) antibodies in cancer patients treated with recombinant IL-2J G Scharenberg, A G Stam, B M von Blomberg, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
European Cytokine Network|August 1, 1990
Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapyM Favrot, R Capdeville, V Combaret, et al.
Journal of Biological Response Modifiers|April 1, 1990
Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinomaM C Favrot, V Combaret, S Negrier, et al.
Pediatric Hematology and Oncology|January 1, 1990
Interleukin 2 immunotherapy in children with neuroblastoma after high-dose chemotherapy and autologous bone marrow transplantationM C Favrot, J Michon, D Floret, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
A phase III study of recombinant interleukin-2, 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal carcinomaS D Heys, O Eremin, E M Ruggeri, et al.
British Journal of Haematology|October 1, 1990
Increased numbers of circulating haematopoietic progenitor cells after treatment with high-dose interleukin-2 in cancer patientsM R Schaafsma, W E Fibbe, D van der Harst, et al.
Molecular Biotherapy|September 1, 1990
Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experienceH Kirchner, A Körfer, P A Palmer, et al.
Bone Marrow Transplantation|September 1, 1989
Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantationM C Favrot, D Floret, S Negrier, et al.
Cancer Immunology, Immunotherapy : CII|July 1, 1994
Persistent augmentation of natural-killer- and T-cell-mediated cytotoxicity in peripheral blood mononuclear cells pulsed in vitro with high-dose recombinant interleukin-2 prior to culturing with a low maintenance doseP A Palmer, J G Scharenberg, B M von Blomberg, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Combination IL-2 and cisplatinum: a promising treatment for bronchioloalveolar carcinoma?V Trillet-Lenoir, D Arpin, A Mercatello, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
The development of anti-interleukin-2 (IL-2) antibodies in cancer patients treated with recombinant IL-2J G Scharenberg, A G Stam, B M von Blomberg, et al.
Pageof 10